Previous studies of Min͞؉ (multiple intestinal neoplasia) mice on a sensitive genetic background, C57BL͞6 (B6), showed that adenomas have lost heterozygosity for the germ-line Apc Min mutation in the Apc (adenomatous polyposis coli) gene. We now report that on a strongly resistant genetic background, AKR͞J (AKR), Min-induced adenoma multiplicity is reduced by about two orders of magnitude compared with that observed on the B6 background. Somatic treatment with a strong mutagen increases tumor number in AKR Min͞؉ mice in an age-dependent manner, similar to results previously reported for B6 Min͞؉ mice. Immunohistochemical analyses indicate that Apc expression is suppressed in all intestinal tumors from both untreated and treated AKR Min͞؉ mice. However, the mechanism of Apc inactivation in AKR Min͞؉ mice often differs from that observed for B6 Min͞؉ mice. Although loss of heterozygosity is observed in some tumors, a significant percentage of tumors showed neither loss of heterozygosity nor Apc truncation mutations. These results extend our understanding of the effects of genetic background on Mininduced tumorigenesis in several ways. First, the AKR strain carries modifiers of Min in addition to Mom1. This combination of AKR modifiers can almost completely suppress spontaneous intestinal tumorigenesis associated with the Min mutation. Second, even on such a highly resistant genetic background, tumor formation continues to involve an absence of Apc function. The means by which Apc function is inactivated is affected by genetic background. Possible scenarios are discussed.
Germ-line mutation of the adenomatous polyposis coli (APC͞ Apc) tumor suppressor gene predisposes both humans and mice to intestinal tumorigenesis (reviewed in ref. 1) . Familial adenomatous polyposis (FAP) is a dominantly inherited human cancer syndrome that results from germ-line APC mutation. Individuals with FAP can develop up to several thousand intestinal tumors, which are located primarily in the colon (2) . The number of tumors observed in FAP individuals seems to be influenced by the site of the germ-line mutation in APC, environmental factors, and the effects of unlinked modifier loci (3) (4) (5) (6) .
Apc Min (Min, multiple intestinal neoplasia) is a nonsense mutation at codon 850 of the mouse APC homolog that predisposes heterozygotes to intestinal tumorigenesis (7, 8) . On the C57BL͞6J (B6) genetic background, Min͞ϩ mice average more than 70 tumors throughout the intestinal tract and rarely live beyond 150 days of age (1) . Somatic N-ethyl-N-nitrosourea (ENU) treatment of B6 Min͞ϩ mice indicates that intestinal tumors are preferentially initiated during the first few weeks of life (9) . Tumor formation in B6 Min͞ϩ mice is invariably associated with somatic loss of the wild-type Apc allele, apparently by chromosome loss (10) . On the (AKR ϫ B6)F 1 genetic background, Min͞ϩ adenoma formation also involves Apc ϩ loss (9) . However, not all tumors show loss of the Apc ϩ marker when the Min mutation is carried on certain other F 1 hybrid genetic backgrounds (11) . Also, regional Apc deletion or nonsense mutation frequently is observed in tumors from Min͞ϩ mice that have been treated somatically with ␥-irradiation or ENU (11, 12) .
Crosses between B6 Min͞ϩ mice and the inbred strain AKR͞J (AKR) led to the identification of the Mom1 locus (13) (14) (15) . Mom1 is a semidominant modifier of intestinal tumor number in Min͞ϩ mice: one AKR allele of Mom1 (Mom1 A ) causes a reduction in tumor number by a factor of two; two copies of Mom1 A reduce tumor multiplicity by a factor of four (16) . Analysis of Min͞ϩ mice carrying a Pla2 g2a transgene indicates that this secreted phospholipase comprises at least a portion of Mom1 (17) .
Beyond Mom1, the AKR strain carries alleles of other loci that modify intestinal tumor number in Min͞ϩ mice (14) . In this paper we have examined the full extent to which the intestinal phenotype of Min͞ϩ mice can be modified by transferring the Apc Min mutation from the sensitive B6 strain onto AKR. We have found that Min-induced intestinal tumorigenesis is almost completely suppressed on the homozygous AKR background. We have observed that a significant percentage of tumors from AKR Min͞ϩ mice do not show Apc ϩ allele loss. Comparing these observations with previous analyses of the (B6 ϫ AKR)F 1 genetic background (10), we conclude that the reduced frequency of Apc ϩ allele loss of AKR is recessive to the high frequency conferred by B6. In this paper, we have asked further whether tumor formation on this highly resistant background requires functional inactivation of both Apc alleles. Immunohistochemical analysis has revealed that Apc gene expression is greatly reduced in all of the tumors that retain the Apc ϩ allelic marker. Several very different scenarios can account for this observation.
MATERIALS AND METHODS
Mice. All mice were bred at the McArdle Laboratory for Cancer Research. Parental AKR mice were purchased from The Jackson Laboratory. All of the AKR Min͞ϩ mice used in these experiments had been backcrossed to AKR for 5-9 generations. Thus, these AKR Min͞ϩ mice were homozygous for AKR alleles at approximately 97% of all loci. The tumor multiplicity of these mice is comparable to that of mice that are now at the 11th backcross generation (data not shown). Animals were genotyped for the presence of the Apc Min mutation by a previously described PCR-based assay (14) . For mutagenesis studies, all mice from a litter (consisting of AKR Min͞ϩ and ϩ͞ϩ mice) were given an i.p. injection of ENU from a single sample as described previously (9) . To control further for ENU variability, litters from each age group were included in each round of ENU treatment. Litters of 10-to 15-day-old B6 Min͞ϩ mice also were included in each round of ENU treatment. Tumor multiplicity in these control mice was comparable to results previously published (9) .
Tumor Scoring and Collection. Intestinal tumors were scored at ϫ10-30 magnification as previously described (9) . For experiments requiring unfixed tissue, tumor and normal intestinal tissues were carefully dissected, with a fresh scalpel blade for each sample. All other samples were fixed overnight in 10% buffered formalin or, for immunohistochemistry, for 1 hr in periodate-lysine-paraformaldehyde (18) .
Quantitative PCR Analysis of Apc. Apc allelic status was assessed by a quantitative PCR assay described previously (10, 12) . This assay generates 123-bp and 144-bp products from the Apc ϩ and Apc Min alleles, respectively. The Apc ϩ ͞Apc Min ratio was determined by quantitation of 32 P-labeled products (10) . To be consistent with previously reported results, the allelic ratios were not corrected for the difference in the sizes of the Apc Min and Apc ϩ amplimers (10, 12) . All samples were independently amplified by PCR at least twice. Only samples that gave repeatable values (within 10%) with signals at least 10-fold above background were included in the results.
Examination of Apc for Truncation Mutations. Codons 680-1230 of the Apc ORF were examined for truncation mutations with an in vitro synthesized protein assay as described previously (12) . This region also includes the germ-line Min nonsense mutation, which served as a positive control for the assay.
Immunohistochemical Analysis of Apc Expression. Tissue samples used for immunohistochemistry were fixed for 1 hr in periodate-lysine-paraformaldehyde. Antibody staining was performed essentially as described by Merritt et al. (19) . Affinity-purified rabbit polyclonal antibody APC2, raised against amino acids 1035-2130 of human APC (a gift from Paul Polakis, Onyx Pharmaceuticals, Richmond, CA), was used at a dilution of 1:100 (20) . Rabbit polyclonal antibody 3122, raised against amino acids 8-347 of human APC, was used at a dilution of 1:500 (21) . The regions of APC used to generate the APC2 and 3122 antibodies are more than 87% identical to mouse Apc at the amino acid level (8) . Slides were lightly counterstained with hematoxylin before dehydration and coverslipping. Staining of each sample always was accompanied by a negative control sample in which the primary antibody was omitted. No staining was observed in any of these control samples (data not shown).
RESULTS
Intestinal Tumor Multiplicity in AKR Min͞؉ Mice. When counting intestinal tumors in B6 Min͞ϩ mice, we typically score four regions representing approximately 40% of the intestine. These regions consist of the entire colon and 4-cm segments from the proximal, middle, and distal small intestine. We consistently have found that B6 Min͞ϩ mice scored in this manner develop 30 Ϯ 10 tumors (1). To examine further the effects of genetic background on Min-dependent intestinal tumorigenesis, we introduced the Min mutation onto the AKR background (see Materials and Methods).
A summary of the intestinal tumor incidence and multiplicity for AKR Min͞ϩ mice is shown in Table 1 . Owing to the low tumor multiplicity of AKR Min͞ϩ mice, the entire length of the small and large intestine was scored for tumors in these animals. Only 43 of 170 AKR Min͞ϩ mice developed even a single intestinal tumor. In total, 53 intestinal tumors were identified from this set of 170 AKR Min͞ϩ mice, yielding a multiplicity of 0.3 tumors per mouse. All of these tumors were located in the small intestine. Correcting for the difference in length of intestine scored, the tumor multiplicity of AKR Min͞ϩ mice represents a reduction by approximately two orders of magnitude from that observed in B6 Min͞ϩ mice (Table 1 ). Only one intestinal tumor was found in a total of 37 AKR Apc ϩ͞ϩ mice. The modifier effects of the Mom1 locus previously were studied by using a strain in which the AKR allele of Mom1 had been introgressed onto the B6 background (15 
Stimulation of Intestinal Adenoma Formation in AKR Min͞؉
Mice by Treatment with ENU. We previously have shown that ENU treatment of B6 Min͞ϩ mice at 5-14 days of age increased tumor multiplicity approximately 3.8-fold, whereas treatment between 20 and 35 days resulted in only a 1.6-fold increase (9) . These results suggest that intestinal tumors in B6 Min͞ϩ mice are preferentially initiated during the first few weeks of life. To investigate the timing of tumor induction in AKR Min͞ϩ mice, we injected Min͞ϩ and ϩ͞ϩ mice with a single dose of ENU at either 9-16 or 27-42 days of age. Mice were sacrificed approximately 150 days after treatment, and tumors were scored along the entire length of the small and large intestine.
ENU treatment significantly increased both the incidence and multiplicity of tumors for each treatment group relative to untreated AKR Min͞ϩ mice (P Ͻ 0.001 for comparisons of tumor number, Wilcoxon rank sum test, Table 2 ). However, a much stronger effect was seen for mice treated at 9-16 days of age. One hundred percent of these mice developed intestinal tumors, with an average multiplicity of 12.8. By contrast, 79% of AKR Min͞ϩ mice treated at 27-42 days of age developed (10) . This pathway for inactivating tumor suppressor function is designated loss of heterozygosity (LOH). Because there were major differences in intestinal tumor multiplicity between B6 Min͞ϩ and AKR Min͞ϩ mice, we investigated whether there are also differences in the somatic events associated with tumor formation.
The allelic status of the Apc locus was examined by a quantitative PCR assay of DNA from 16 intestinal tumors from untreated AKR Min͞ϩ mice. Tumors from the AKR Min͞ϩ mice tend to be quite small; however, the amount of stromal cell infiltration seemed comparable to that observed for tumors from B6 Min͞ϩ mice. To obtain samples enriched for normal or tumor cells, we prepared DNA from cells that were scraped from fixed and sectioned tissue samples. The index of heterozygosity at the Apc locus, Het Apc , was defined as the Apc ϩ ͞Apc Min band ratio of the tumor DNA sample, normalized to the band ratio determined in parallel for the DNA sample from adjacent normal tissue (see Fig. 1 ). If the Het Apc was Ն0.64, we concluded that the Apc ϩ allelic marker persisted. By this criterion, 37% (6͞16) of the fixed tumors from untreated AKR Min͞ϩ mice maintained heterozygosity for the Apc marker (Fig. 1) .
Tumors from AKR Min͞ϩ mice that maintained the Apc ϩ allelic marker might have acquired mutations within the Apc ϩ allele. We previously have found that at least 27% (25͞91) of intestinal tumors from ENU-treated B6 Min͞ϩ mice that fail to show LOH instead carry a detectable somatic Apc truncation mutation (12) . To begin to address this possibility for the AKR Min͞ϩ case, we analyzed tumors from both untreated and ENU-treated mice for Apc truncation mutations, using the in vitro synthesized protein (IVSP) assay. In this initial analysis we focused on the region of Apc between codons 680 and 1230, because all of the 25 truncation mutations found in tumors from ENU-treated B6 Min͞ϩ mice were found in that region of the gene. A set of frozen tissue samples was collected for these experiments, because the IVSP assay is incompatible with nucleic acids prepared from fixed tissue.
Frozen tumors from untreated and ENU-treated AKR Min͞ϩ mice were analyzed. Twenty tumors (2͞6 and 18͞36, respectively) maintained Apc heterozygosity (Fig. 1) . Of these, two untreated and 10 ENU-treated tumors were successfully examined by the in vitro synthesized protein assay. In contrast to ENU-treated B6 Min͞ϩ mice, where 25͞91 of the tumors that maintained the Apc Cytoplasmic Apc staining was observed in cells from normal intestinal epithelia of B6 Min͞ϩ and AKR Min͞ϩ mice (Fig.  2) . Apc staining was more intense for cells in the upper half of crypts than at the base. The columnar epithelial cells of the intestinal villi showed light, but consistent, Apc staining (Fig.  2) . Both 3122 and APC2 gave similar results, and this pattern of expression is consistent with previous reports of APC͞Apc expression (18, (22) (23) (24) . However, there were some differences between 3122 and APC2 with respect to intracellular localization of Apc. Each antibody detected Apc expression in the basal, lateral, and apical cytoplasm (Fig. 2) . However, 3122 stained the apical cytoplasm much more intensely than the basal cytoplasm, whereas APC2 strongly stained both the basal and the apical cytoplasm (compare Fig. 2 B and F) .
In intestinal tumors from B6 Min͞ϩ mice, Apc expression was essentially undetectable with either antibody (Fig. 2 A and  B) . Because the 3122 antibody should be capable of recogniz- Entire litters were treated with ENU as described in Materials and Methods. The entire length of the small and large intestine was scored. The average age (post-ENU) for the ENU-treated mice was 156 days. The average age for the untreated mice was 152 days. No tumors were found in any of 39 ENU-treated AKR Apc ϩ͞ϩ mice, 12 of which were treated at 9-16 days of age and the remaining 27 mice at 27-42 days of age. The average post-ENU age of the Apc ϩ͞ϩ mice was 138 days. (Fig. 2 C-F) . For three of the 18 samples, the APC2 signal was too light to be reliably interpreted in normal and tumor cells. Twelve of the 15 scorable tumors also were analyzed by quantitative PCR: eight maintained heterozygosity for the Min marker (two untreated and six ENU-treated). In the cells of all scorable samples, Apc expression detected by immunohistochemistry was significantly reduced relative to staining levels in adjacent normal cells (Fig. 2 C-F) . However, some residual Apc staining was observed in all but two of the AKR Min͞ϩ tumors. This residual staining was not found in the most dysplastic regions of the tumors. Because this residual signal was observed even in tumors classified as involving LOH, it may be nonspecific. Taken together, these results indicate that normal Apc function(s) must be attenuated for both spontaneous and ENU-induced intestinal tumor formation in AKR Min͞ϩ mice. However, the mechanism(s) of Apc inactivation in tumors of AKR Min͞ϩ mice frequently differs from that observed for B6 Min͞ϩ mice.
DISCUSSION
The Strong Dependence of a Mouse Cancer Model on Genetic Background. Manipulation of the genetic background alone can reduce intestinal tumor multiplicity in mice carrying the Apc Min mutation by about two orders of magnitude (Table  1) . Indeed, 75% of Min͞ϩ mice on the AKR genetic background were tumor free at 6 months of age. This finding contrasts sharply with the B6 background, where 100% of Min͞ϩ animals develop numerous intestinal tumors by 2-3 months of age (7). Furthermore, from the entire set of 170 AKR Min͞ϩ mice examined, only one colonic tumor was identified-in an ENU-treated animal. These results highlight the importance of evaluating genetic background when studying the effects of any germ-line mutation in the mouse. To appreciate fully the phenotype(s) associated with a gene, it seems imperative to study each germ-line mutation for that gene on several different genetic backgrounds.
Even on the highly resistant AKR genetic background, intestinal tumors in Min͞ϩ mice appear to initiate preferentially early in life. A 26-fold increase in tumor number was observed for mice treated with ENU at 9-16 days, whereas mice treated at 27-42 days showed only a 3.8-fold increase in tumor number compared with the untreated set. The enhanced susceptibility of younger B6 and AKR Min͞ϩ mice to tumor formation may be influenced by developmental changes that occur in the intestine during the first few weeks of life. Intestinal crypt purification and expansion are two changes that may be important contributors to this susceptibility. The effect of the AKR genetic background on tumor multiplicity in Min͞ϩ mice does not seem to involve alteration of the age dependence of tumorigenesis.
The mechanism of somatic Apc inactivation also was influenced by the genetic background. In contrast to the 100% LOH observed for untreated B6 mice, 36% (8͞22) of the tumors from untreated AKR Min͞ϩ mice failed to show LOH by our assay. Also, in our previous analysis of ENU-treated B6 Min͞ϩ mice, 25͞91 tumors lacking LOH had shown truncations, all between codons 700 and 1215 (12) . No such truncation mutations in Apc were observed in 12 tumors from AKR Min͞ϩ mice. Consider the null hypothesis that the AKR pattern does not differ from the B6 pattern. On this hypothesis, the probability that no truncations would be found in this sample is 0.036 (Fisher exact test). Thus ENU treatment on the AKR background either alters the Apc mutational spectrum relative to B6 or stimulates tumorigenesis by influencing loci other than Apc. Mutational activation of ␤-catenin would be one possibility for this latter scenario, but note that, in contrast to the reported case (25) , the Apc locus always is silenced in the cases we have studied.
There are numerous intriguing possibilities raised by these results. First, it is reasonable to expect that tumor multiplicity would be influenced by factors that affect the rate or frequency of somatic Apc segregation. It is worth noting that even a small change in mitotic fidelity could have a large effect on tumor number in a tissue as mitotically active as the intestinal epithelium. The possibility of differences between the B6 and AKR strains in modifier loci that influence mitotic segregation requires further investigation.
At least in respect to the Apc locus and mouse chromosome 18, we classify B6 as mitotically unstable and AKR as relatively more stable. The instability generated by B6 is dominant to the stability of AKR, because adenomas in (AKRϫB6)F 1 animals show a 100% incidence of LOH (10) . These germ-line differences in frequency of LOH are interesting to compare with recent observations on cell lines derived from human colon cancer. Lengauer and his colleagues (26) have described two classes of cell lines from human colonic tumors, one class karyotypically unstable and the other karyotypically stable. They have suggested that the normal stem cell precursor for colonic tumors is karyotypically stable (27) . Cell fusion analysis indicates that karyotypic instability is at least partially dominant to stability (26) . One cause adduced for dominant karyotypic instability is mutation of the mitotic checkpoint gene, Bub1 (28) . Several lines of further investigation are required to ascertain whether the difference in LOH frequency between the AKR and B6 backgrounds reflects generalized karyotypic instability, a difference in stem cell source for tumors (29) , or germ-line differences at mitotic checkpoint loci such as Bub1.
Mom1 is the first mapped polymorphic modifier locus that affects intestinal tumor number in Min͞ϩ mice. However, Mom1 cannot fully account for the reduced tumor multiplicity observed in AKR Min͞ϩ mice (Table 1) . Homozygosity for the AKR-resistance allele of Mom1 reduces tumor multiplicity by a factor of four relative to B6 Min͞ϩ mice (16) . Thus, tumor number is reduced by an additional factor of 60 by making the Min mutation congenic on the AKR background. Clearly, the AKR strain carries alleles at loci other than Mom1 that strongly influence Min-induced tumorigenesis.
Apc as a Canonical Tumor Suppressor Locus. The canonical genetic pathway for inactivating a ''tumor suppressor'' function involves two hits, one affecting each allele of an autosomal locus (30) . When this pathway is inefficient, other mechanisms can come into play. We identified 32 tumors from AKR Min͞ϩ mice in which Apc did not appear to be somatically inactivated either by allele loss or by truncation mutation ( Fig. 1 and  above) . The Apc-negative status of this set of tumors cannot be readily explained by missense mutations in the wild-type allele. Missense substitutions should not simultaneously affect the multiple epitopes detected by the 3122 and APC2 antibodies. But note that the stimulation of adenoma formation on the AKR background by ENU is observed only in Apc Min ͞ϩ heterozygotes. Thus, a two-hit hypothesis remains tenable: a germ-line lesion in Apc combined with a somatic mutation in an interacting locus. The initial two-hit hypothesis of Knudson (30) did not restrict the hits to the two alleles of one locus. The complexities of the genetics of Wilms' tumor have been interpreted by such two-locus models (31) .
Although the primary mechanism of Apc inactivation may differ between B6 and AKR Min͞ϩ mice, all intestinal tumors examined from both untreated and ENU-treated AKR Min͞ϩ mice showed a dramatic deficiency in Apc expression relative to normal cells (Fig. 2) . We can only speculate at this stage as to how the Apc ϩ allele becomes silent in the apparent absence of LOH or somatic mutation (32) . This result demonstrates that lack of Apc tumor suppressor function is critical for tumor formation in both strains. These findings support the hypothesis of APC͞Apc as a unique ''gatekeeper'' gene that functions as a critical negative regulator mediating intestinal epithelial homeostasis (33) . Whether all neoplastic pathways are negatively regulated by a unique ''gatekeeper'' is an interesting issue for the future.
